Your patients break the rules DXA was built on.
Type 2 diabetes. Long-term glucocorticoids. Chronic kidney disease. Post-transplant. Aromatase inhibitors, proton pump inhibitors, chemotherapy. In every one of these conditions, bone quality deteriorates while density stays put — so the T-score reads reassuring right up until the fracture.
The problem is mechanistic, not statistical. In each of these conditions, bone fragility develops through pathways density doesn’t track: advanced glycation end-products stiffening collagen in diabetes, suppressed bone formation and altered mineralization under steroids, disordered mineral metabolism in CKD. The mineral content can hold steady — or rise — while the tissue underneath becomes brittle.
Why strength is the better measurement
A dam doesn’t fail because it’s thin. It fails because a crack finds a weakness and runs.
Density tells you how thick the wall is. It can’t tell you whether the concrete is sound.
OsteoProbe measures bone material strength (BMSi) — a tissue-level property that correlates with bone toughness in laboratory testing and can be low even when density is normal or high, as shown in type-2 diabetes, HIV, and CKD.
A measure that moves on a useful timescale
DXA is typically repeated every one to two years. That interval can’t answer the question you actually face: has anything actually changed — or do we wait two years to find out?
Bone material quality moves faster and can be measured more often.
Published data show measurable BMSi change within 7 weeks of starting therapy, on a timescale density can’t capture.
In women who fractured despite ≥4 years of oral bisphosphonate therapy, BMSi was markedly lower than in those who didn’t (73.8 vs 81.6; p = 0.001) and discriminated better than DXA (AUC 0.82).
Adding it to your practice
- Performed by your RN
- No radiation — repeat as often as clinically appropriate
- Well-tolerated — pain scores at or below 1 of 10 NRS
- CPT III code 0547T issued; coverage currently case-by-case